Genmab A (GMAB) Restructuring Costs (2024 - 2026)

Genmab A's (GMAB) quarterly Restructuring Costs came in at -$32.0 million in Q2 2026, up 28.89% quarter-over-quarter from -$45.0 million in Q1 2026.

Analysis

Genmab A (GMAB) Restructuring Costs (2024 - 2026) Analysis & Trends

Genmab A (GMAB) has reported Restructuring Costs for 2 consecutive years, with -$32.0 million the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, Restructuring Costs changed N/A year-over-year to -$32.0 million; the trailing twelve-month figure through Jun 2026 stood at -$120.0 million (down 1.69% YoY), and the FY2025 full-year result was -$185.0 million, down 330.23% from the prior year.
Restructuring Costs climbed to -$32.0 million in Q2 2026 per GMAB's latest filing, from -$45.0 million in the prior quarter.
Across five years, Restructuring Costs topped out at -$32.0 million in Q2 2026 and bottomed at -$45.0 million in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	208.48 Bn	194.49 Bn	7.24 Bn
2	Gilead Sciences	186.29 Bn	183.02 Bn	6.22 Bn
3	Vertex Pharmaceuticals	128.79 Bn	120.93 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	80.66 Bn	72.67 Bn	3.93 Bn
5	Moderna	61.46 Bn	56.32 Bn	52.00 Mn
6	Argenx Se	61.28 Bn	56.10 Bn	1.37 Bn
7	Alnylam Pharmaceuticals	32.04 Bn	28.73 Bn	992.69 Mn
8	Biogen	31.84 Bn	30.56 Bn	1.96 Bn
9	Roivant Sciences	28.74 Bn	29.43 Bn	1.16 Mn
10	Genmab A	2.23 Bn	728.64 Mn	1.07 Bn

Historic Data

Download Data